<table-wrap id="T2" position="float"> 
 <label>Table 2</label>  
 <p>KRAS and treatment response to Cetuximab-containing regiments in chemotherapy-na&iuml;ve patients with colorectal carcinoma.</p>  
 <table frame="hsides" rules="groups"> 
  <thead> 
   <tr> 
    <td align="left"> 
     <bold>
      Study
     </bold> </td>
    <td align="left"> 
     <bold>
      Treatments
     </bold> </td>
    <td align="left"> 
     <bold>
      KRAS
     </bold> </td>
    <td align="center"> 
     <bold>
      N (%)
     </bold> </td>
    <td align="left"> 
     <bold>
      RR, N (%)
     </bold> </td>
    <td align="center"> 
     <bold>
      TTP
     </bold> 
     <break></break> 
     <bold>
      (months)
     </bold> </td>
    <td align="center"> 
     <bold>
      OS
     </bold> 
     <break></break> 
     <bold>
      (months)
     </bold> </td>
    <td align="left"> 
     <bold>
      Remarks
     </bold> </td> 
   </tr> 
  </thead> 
  <tbody> 
   <tr> 
    <td align="left">Bokemeyer, 2008</td>
    <td align="left">FOLFOX + CTX</td>
    <td align="left">WT</td>
    <td align="left">61</td>
    <td align="left">37 (60.7%)</td>
    <td align="center">7.7</td>
    <td align="center">NA</td>
    <td align="left">KRAS MT has worse RR and TTP.
     <break></break>Cetuximab may have detrimental effects in KRAS MT.</td> 
   </tr> 
   <tr> 
    <td></td>
    <td></td>
    <td align="left">MT</td>
    <td align="left">52 (46.0%)</td>
    <td align="left">17 (32.7%)</td>
    <td align="center">5.5</td>
    <td align="center">NA</td>
    <td></td> 
   </tr> 
   <tr> 
    <td></td>
    <td align="left">FOLFOX</td>
    <td align="left">WT</td>
    <td align="left">73</td>
    <td align="left">27 (37.0%)</td>
    <td align="center">7.2</td>
    <td align="center">NA</td>
    <td></td> 
   </tr> 
   <tr> 
    <td></td>
    <td></td>
    <td align="left">MT</td>
    <td align="left">47 (39.2%)</td>
    <td align="left">23 (48.9%)</td>
    <td align="center">8.6</td>
    <td align="center">NA</td>
    <td></td> 
   </tr> 
   <tr> 
    <td align="left">Cervantes, 2008</td>
    <td align="left">CTX</td>
    <td align="left">WT</td>
    <td align="left">29</td>
    <td align="left">8 (27.6%)</td>
    <td align="center">NA</td>
    <td align="center">NA</td>
    <td align="left">Patients were treated with CTX first, then in combination with chemo.
     <break></break>KRAS MT has worse RR and TTP.</td> 
   </tr> 
   <tr> 
    <td></td>
    <td></td>
    <td align="left">MT</td>
    <td align="left">19 (39.6%)</td>
    <td align="left">0</td>
    <td align="center">NA</td>
    <td align="center">NA</td>
    <td></td> 
   </tr> 
   <tr> 
    <td></td>
    <td align="left">CTX + FOLFIRI</td>
    <td align="left">WT</td>
    <td align="left">29</td>
    <td align="left">16 (55.2%)</td>
    <td align="center">9.4</td>
    <td align="center">NA</td>
    <td></td> 
   </tr> 
   <tr> 
    <td></td>
    <td></td>
    <td align="left">MT</td>
    <td align="left">19 (39.6%)</td>
    <td align="left">6 (31.6%)</td>
    <td align="center">5.6</td>
    <td align="center">NA</td>
    <td></td> 
   </tr> 
   <tr> 
    <td align="left">Punt, 2008</td>
    <td align="left">CapOxBev+CTX</td>
    <td align="left">WT</td>
    <td align="left">153</td>
    <td align="left">NA</td>
    <td align="center">10.5</td>
    <td align="center">22.2</td>
    <td align="left">KRAS MT has worse TTP, and OS.
     <break></break>Cetuximab may have detrimental effects in KRAS MT.</td> 
   </tr> 
   <tr> 
    <td></td>
    <td></td>
    <td align="left">MT</td>
    <td align="left">93 (37.8%)</td>
    <td align="left">NA</td>
    <td align="center">8.6</td>
    <td align="center">19.1</td>
    <td></td> 
   </tr> 
   <tr> 
    <td></td>
    <td align="left">CapOxBev</td>
    <td align="left">WT</td>
    <td align="left">152</td>
    <td align="left">NA</td>
    <td align="center">10.7</td>
    <td align="center">23.0</td>
    <td></td> 
   </tr> 
   <tr> 
    <td></td>
    <td></td>
    <td align="left">MT</td>
    <td align="left">103 (40.4%)</td>
    <td align="left">NA</td>
    <td align="center">12.5</td>
    <td align="center">24.9</td>
    <td></td> 
   </tr> 
   <tr> 
    <td align="left">Van Custem, 2008</td>
    <td align="left">FOLFIRI + CTX</td>
    <td align="left">WT</td>
    <td align="left">172</td>
    <td align="left">102 (59.3%)</td>
    <td align="center">9.9</td>
    <td align="center">NA</td>
    <td align="left">KRAS MT has worse RR and TTP.
     <break></break>Cetuximab may have detrimental effects in KRAS MT.</td> 
   </tr> 
   <tr> 
    <td></td>
    <td></td>
    <td align="left">MT</td>
    <td align="left">105 (37.9%)</td>
    <td align="left">38 (36.2%)</td>
    <td align="center">7.6</td>
    <td align="center">NA</td>
    <td></td> 
   </tr> 
   <tr> 
    <td></td>
    <td align="left">FOLFIRI</td>
    <td align="left">WT</td>
    <td align="left">176</td>
    <td align="left">76 (43.2%)</td>
    <td align="center">8.7</td>
    <td align="center">NA</td>
    <td></td> 
   </tr> 
   <tr> 
    <td></td>
    <td></td>
    <td align="left">MT</td>
    <td align="left">87 (33.1%)</td>
    <td align="left">35 (40.2%)</td>
    <td align="center">8.1</td>
    <td align="center">NA</td>
    <td></td> 
   </tr> 
  </tbody> 
 </table> 
 <table-wrap-foot> 
  <p>Abbreviations: CTX = cetuximab; PAN = panitumumab; IRI = irinotecan; Ox = oxaliplatin; Cap = capcitabine; Bev = bevacizumab; BSC = best supportive care; WT = wild type; MT = mutant type; NA = Not Available or Not Applicable; RR = objective response rate (complete response + partial response); TTP = time to progression; OS = overall survival.</p> 
 </table-wrap-foot> 
</table-wrap>